American Academy of Neurology. (2004). Efficacy and tolerability of the new anti-epileptic drugs 1: Treatment of new onset epilepsy. Retrieved November 9, 2005, from http://www.neurology.org/cgi/reprint/62/8/1252.pdf
2.
BenbadisS.R., & TatumW.O. (2001). Advances in the treatment of epilepsy. American Family Physician, 64(1), 91–98.
FrenchJ.A., KannerA.M., BautistaJ., Abou-KhalilB., BrowneT., HardenC.L., TheodoreW.H., BazilC., SternJ., SchachterS.C., BergenD., HirtzD., MontourisG.D., NespecaM., GidalB., MarksW.J.Jr., TurkW.R., FischerJ.H., BourgeoisB., WilnerA., FaughtR.E.Jr., SachdeoR.C., BeydounA., GlauserT.A., Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Quality Standards Subcommittee of the American Academy of Neurology, & American Epilepsy Society. (2004). Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Neurology, 62, 1252–1260.
KingM.A., NewtonM.R., JacksonG.D., FittG.J., MitchellL.A., SilvapulleM.J., & BerkovicS.F. (1998). Epileptology of the first-seizure presentation: A clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients. Lancet, 352(9133), 1007–1011.
8.
KwanP., & BrodieM.J. (2000). Early identification of refractory epilepsy. New England Journal of Medicine, 342, 314–319.
9.
ScheepersB., CloughP., & PicklesC. (1998). The misdiagnosis of epilepsy: Findings of a population study. Seizure, 7, 403–406.